Westwood Holdings Group Inc. raised its holdings in Becton Dickinson and Co (NYSE:BDX) by 0.7% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,033,484 shares of the medical instruments supplier’s stock after purchasing an additional 7,609 shares during the period. Becton Dickinson and makes up about 1.7% of Westwood Holdings Group Inc.’s portfolio, making the stock its 6th largest holding. Westwood Holdings Group Inc. owned approximately 0.39% of Becton Dickinson and worth $221,227,000 as of its most recent SEC filing.
A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Legacy Advisors LLC increased its position in Becton Dickinson and by 7,000.0% during the 4th quarter. Legacy Advisors LLC now owns 497 shares of the medical instruments supplier’s stock worth $106,000 after purchasing an additional 490 shares in the last quarter. Amica Retiree Medical Trust increased its position in Becton Dickinson and by 325.0% during the 4th quarter. Amica Retiree Medical Trust now owns 510 shares of the medical instruments supplier’s stock worth $109,000 after purchasing an additional 390 shares in the last quarter. Almanack Investment Partners LLC. acquired a new position in Becton Dickinson and during the 4th quarter worth approximately $109,000. FTB Advisors Inc. increased its position in Becton Dickinson and by 114.2% during the 4th quarter. FTB Advisors Inc. now owns 544 shares of the medical instruments supplier’s stock worth $116,000 after purchasing an additional 290 shares in the last quarter. Finally, Advisors Preferred LLC acquired a new position in Becton Dickinson and during the 4th quarter worth approximately $126,000. 83.37% of the stock is owned by hedge funds and other institutional investors.
A number of equities analysts recently issued reports on BDX shares. Zacks Investment Research upgraded shares of Becton Dickinson and from a “hold” rating to a “buy” rating and set a $240.00 price objective for the company in a research report on Wednesday, January 3rd. Deutsche Bank set a $260.00 price objective on shares of Becton Dickinson and and gave the stock a “buy” rating in a research report on Friday, December 29th. Argus upped their price target on shares of Becton Dickinson and to $235.00 and gave the company a “buy” rating in a research report on Thursday, December 14th. They noted that the move was a valuation call. Bank of America restated a “buy” rating and issued a $260.00 price target on shares of Becton Dickinson and in a research report on Friday, January 19th. Finally, Morgan Stanley upped their price target on shares of Becton Dickinson and from $245.00 to $250.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 7th. Six investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average price target of $238.00.
In related news, Director Timothy M. Ring sold 176 shares of the stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $218.27, for a total transaction of $38,415.52. Following the transaction, the director now directly owns 170,688 shares of the company’s stock, valued at $37,256,069.76. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, Director Timothy M. Ring sold 269,661 shares of the stock in a transaction on Thursday, February 8th. The stock was sold at an average price of $217.82, for a total transaction of $58,737,559.02. Following the transaction, the director now directly owns 295,753 shares in the company, valued at $64,420,918.46. The disclosure for this sale can be found here. Over the last three months, insiders have sold 281,108 shares of company stock worth $61,321,396. 1.00% of the stock is owned by insiders.
Becton Dickinson and Co (NYSE:BDX) traded up $0.19 during trading hours on Friday, hitting $224.34. 168,888 shares of the stock were exchanged, compared to its average volume of 1,448,110. The company has a debt-to-equity ratio of 1.04, a quick ratio of 0.93 and a current ratio of 1.54. Becton Dickinson and Co has a 12 month low of $175.66 and a 12 month high of $248.39. The company has a market cap of $59,510.52, a price-to-earnings ratio of 171.11, a P/E/G ratio of 1.62 and a beta of 1.18.
Becton Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, February 6th. The medical instruments supplier reported $2.48 EPS for the quarter, beating the Zacks’ consensus estimate of $2.41 by $0.07. Becton Dickinson and had a net margin of 2.71% and a return on equity of 16.19%. The company had revenue of $3.08 billion for the quarter, compared to analyst estimates of $3.05 billion. During the same period in the prior year, the firm posted $2.33 EPS. The company’s quarterly revenue was up 5.4% on a year-over-year basis. equities analysts expect that Becton Dickinson and Co will post 10.94 EPS for the current year.
The business also recently announced a quarterly dividend, which will be paid on Friday, March 30th. Investors of record on Friday, March 9th will be paid a dividend of $0.75 per share. This represents a $3.00 annualized dividend and a yield of 1.34%. The ex-dividend date of this dividend is Thursday, March 8th. Becton Dickinson and’s dividend payout ratio is presently 229.01%.
COPYRIGHT VIOLATION NOTICE: This story was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this story on another publication, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this story can be viewed at https://www.dispatchtribunal.com/2018/03/16/becton-dickinson-and-co-bdx-is-westwood-holdings-group-inc-s-6th-largest-position.html.
Becton Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton Dickinson and Co (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and and related companies with MarketBeat.com's FREE daily email newsletter.